Get the Stockscreener App
3.345
1.61%
-0.075
Kiora Pharmaceuticals Inc stock is traded at $3.345, with a volume of 537.
It is down -1.61% in the last 24 hours and down -3.58% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$3.42
Open:
$3.4119
24h Volume:
537
Relative Volume:
0.02
Market Cap:
$10.35M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.3632
EPS:
-9.2108
Net Cash Flow:
$7.14M
1W Performance:
-0.94%
1M Performance:
-3.58%
6M Performance:
-33.10%
1Y Performance:
-33.23%
1-Day Range:
$3.4119
$3.4119
1-Week Range:
$3.16
$3.4899
52-Week Range:
$3.00
$8.982
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
781-788-8869
Address
332 ENCINITAS BOULEVARD, ENCINITAS
Compare KPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| KPRX | 3.4119 | 10.35M | 0 | 2.81M | 7.14M | -9.2108 |
| VRTX | 448.66 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.56 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.27 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharma Reports Strong Q3: $29M Cash Position, FDA Study Approval Boost Outlook | KPRX Stock News - StockTitan
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com
Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia
Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan
CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK
Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):